UK markets open in 5 hours 6 minutes
NIKKEI 225
37,940.99 -519.09 (-1.35%) HANG SENG
17,151.13 -50.14 (-0.29%) CRUDE OIL
82.64 -0.17 (-0.21%) GOLD FUTURES
2,331.00 -7.40 (-0.32%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,564.98 -2,048.19 (-3.82%)
Puma Biotechnology, Inc. (PBYI)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 5.1300 |
| Open | 5.0900 |
| Bid | 4.7900 x 300 |
| Ask | 4.8500 x 400 |
| Day's range | 4.7700 - 5.1300 |
| 52-week range | 2.1300 - 7.7300 |
| Volume | |
| Avg. volume | 584,414 |
| Market cap | 246.821M |
| Beta (5Y monthly) | 1.31 |
| PE ratio (TTM) | 10.73 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
LOS ANGELES, April 18, 2024--Puma Biotechnology will issue it's 1Q-2024 results after the close on May 2, 2024, and host a conference call to discuss results at 1:30 p.m. PDT.
- Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, April 03, 2024--Puma Biotechnology reported an inducement award granted to one new hire in March 2024, as required under Nasdaq Listing Rule 5635(c)(4).
- Business Wire
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
LOS ANGELES, March 20, 2024--The FDA cleared Puma Biotechnology's IND for Alisertib in HER2-negative, hormone receptor-positive metastatic breast cancer.
© 2024 Yahoo. All rights reserved.